Taylor S A, Fleming T, Von Hoff D D, McCracken J D, Bukowski R M, Talley R W, Natale R B, Guy J T, Samlowski W E, Costanzi J H
University of Kansas Medical Center.
Invest New Drugs. 1990 Feb;8(1):77-80. doi: 10.1007/BF00216928.
Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients.
患有晚期胰腺癌且未接受过化疗的患者参加了米托蒽醌的II期试验。根据胆红素定义的肝功能障碍调整剂量。24例胆红素小于或等于1.5mg%的患者接受静脉注射米托蒽醌12mg/m²，每三周重复一次。以白细胞减少形式出现的骨髓抑制是主要毒性。24例可评估患者均无反应。
